- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: PD-L1 high TNBC
Total 25598 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Zhongnan HospitalRecruiting
-
Baodong QinUnknown
-
Shanghai Zhongshan HospitalRecruiting
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Lene Meldgaard KnudsenIO BiotechTerminatedSmoldering Multiple MyelomaDenmark
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
Thomas MarronRecruiting
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
The Second Hospital of Nanjing Medical UniversityUnknownPrimary Hepatocellular Carcinoma
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Sichuan UniversityRecruitingMalignant Ascites | Malignant Peritoneal Effusion | Serous Cavity MetastatisesChina
-
Sichuan UniversityRecruitingPleural Effusion, Malignant | Peritoneal Carcinoma MetastaticChina
-
Genentech, Inc.Completed
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; Gilead SciencesRecruitingBreast Cancer | Triple Negative Breast Cancer | PD-L1 NegativeUnited States
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Lene Meldgaard KnudsenCompleted
-
Naestved HospitalRecruitingNon-small Cell Lung Cancer | Malignant Pleural EffusionDenmark
-
Merck Sharp & Dohme LLCRecruitingBladder CancerCanada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
-
Merck Sharp & Dohme LLCActive, not recruitingTriple Negative Breast NeoplasmsBrazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Sarah GoldbergMirati Therapeutics Inc.TerminatedLung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | SitravatinibUnited States
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Eli Lilly and CompanyActive, not recruitingPancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
-
Maastricht Radiation OncologyCompletedProstate Cancer | PD-L1Netherlands